Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI

Achard, Vérane; Lamanna, Giorgio; Denis, Antoine; Perrot, Thomas Benoît De; Mainta, Ismini; Ratib, Osman; Iselin, Christophe; Miralbell, Raymond; Garibotto, Valentina; Zilli, Thomas

doi:10.1007/s12032-019-1291-z

Cited by 15 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET/MRI was used to seek biochemical recurrences of PCa in a total of 598 patients [8,26,32,34,39,42,51,52,56]. Taking the studies concerned together, the recurrent disease detection rate achieved with PET/MRI ranged between 54.5 [56] and 97% [8] (Table 2).…”

Section: Pet/mri In Cases Of Biochemical Disease Recurrencementioning

confidence: 99%

“…Grubmuller et al [34] confirmed as much. A number of authors [26,28,34,51] detected a change in patient management prompted by PET/MRI findings, in proportions of cases ranging from 53.2 to 74.6%. Based on the study by Kranzbuhler et al [56], including PET/MRI in the diagnostic workup could prompt changes to radiotherapy planning for 39.4% of patients.…”

Section: Pet/mri In Cases Of Biochemical Disease Recurrencementioning

confidence: 99%

“…Judging from the data reported by de Perrot et al [13] and Muehlematter et al [41], PET/MRI was more sensitive than mpMRI in identifying primary tumor in the peripheral zone of prostate gland, and in revealing extracapsular extension and seminal vesicle infiltration. On the other hand, mpMRI provided more information about disease recurrence in the prostatic fossa [30,51]. As for the detection of lymph node and distant metastases, PET/MRI was more sensitive than mpMRI, in both staging [38] and restaging [32,51].…”

Section: Pet/mri Vs Mpmrimentioning

confidence: 99%

See 2 more Smart Citations

PET/MRI in prostate cancer: a systematic review and meta-analysis

Evangelista

Zattoni

Cassarino

et al. 2020

Eur J Nucl Med Mol Imaging

105

View full text Add to dashboard Cite

Aim In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). Materials and methods A literature search was conducted in three different databases. The terms used were “choline” or “prostate-specific membrane antigen - PSMA” AND “prostate cancer” or “prostate” AND “PET/MRI” or “PET MRI” or “PET-MRI” or “positron emission tomography/magnetic resonance imaging.” All relevant records identified were combined, and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was < 10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table. Results Fifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients. Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively). Conclusions PET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease, particularly when radiolabeled PSMA was used.

show abstract

Section: Pet/mri In Cases Of Biochemical Disease Recurrencementioning

confidence: 99%

Section: Pet/mri In Cases Of Biochemical Disease Recurrencementioning

confidence: 99%

Section: Pet/mri Vs Mpmrimentioning

confidence: 99%

See 1 more Smart Citation

PET/MRI in prostate cancer: a systematic review and meta-analysis

Evangelista

Zattoni

Cassarino

et al. 2020

Eur J Nucl Med Mol Imaging

105

View full text Add to dashboard Cite

show abstract

“…For instance, Eiber et al [16] found an overall detection rate of 84% in 75 patients with median PSA levels of 2.6 ng/mL (range 0.2-88 ng/mL). In 58 patients, Achard et al [17] found an overall positivity rate for the FCH hybrid PET/MRI of 58.6%, while it was 44% among patients with PSA levels ≤ 2 ng/ml and 12.5% for those with PSA levels < 0.5 ng/mL. Similar results were reported by Riola Parada et al [2] who found an overall detection rate of 55.56% for FCH PET/MRI in 27 patients with a median PSA level of 2.94 ng/mL (range 0.18-10 ng/mL).…”

Section: Discussionmentioning

confidence: 97%

“…Previous publications reported on overall detection rates for FCH or 11C-choline PET/MRI in recurrent PCa [2,[16][17][18]. For instance, Eiber et al [16] found an overall detection rate of 84% in 75 patients with median PSA levels of 2.6 ng/mL (range 0.2-88 ng/mL).…”

Section: Discussionmentioning

confidence: 99%

Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer

et al. 2021

View full text Add to dashboard Cite

Objectives The aims of the study were (i) to examine the PCa detection rate of 18F-choline (FCH) PET/MRI and (ii) to assess the impact of PET/MRI findings in patients with PCa who develop OMD using PSA response as a biomarker. Methods We retrospectively analyzed a cohort of 103 patients undergoing FCH PET/MRI for biochemical recurrence of PCa. The inclusion criteria were (1) previous radical prostatectomy (RP) with or without adjuvant radiotherapy (RT); (2) PSA levels available at the time of PET; (3) OMD, defined as a maximum of 5 lesions on PET/MRI; and (4) follow-up data available for at least 6 months after PET. All images were reviewed by two nuclear medicine physicians and interpreted with the support of two radiologists. Results Seventy patients were eligible for the study: 52 patients had a positive FCH PET/MRI and 18 had a negative scan. The overall PCa detection rates for MRI, PET, and PET/MRI were 65.7%, 37.1%, and 74.3%, respectively. Thirty-five patients were treated with radiotherapy (RT), 16 received hormonal therapy (HT), 3 had a combined therapy (RT + HT), and 16 (23%) underwent PSA surveillance. At follow-up, PSA levels decreased in 51 patients (73%), most of whom had been treated with RT or RT + HT. Therapeutic management was guided by PET/MRI in 74% of patients, which performed better than MRI alone (68% of patients). Conclusion FCH PET/MRI has a higher detection rate than MRI or PET alone for PCa patients with OMD and PSA levels > 0.5 ng/mL, prompting a better choice of treatment.

show abstract